Uterine Flushing With Human Chorionic Gonadotrophin and Unexplained Infertility

The Impact of Uterine Flushing With Human Chorionic Gonadotrophin Before Intrauterine Insemination on Pregnancy and Live Birth Rates in Women With Unexplained Infertility: A Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03461601

Enrollment

210

Registered

2018-03-12

Start date

2014-06-01

Completion date

2017-06-01

Last updated

2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unexplained Infertility

Brief summary

A prospective randomized study included 210 women with Unexplained infertility subjected to combined ovarian stimulation and Intrauterine insemination (IUI). Two equal groups. Study group, subjected to uterine flushing with Human chorionic gonadotropin (HCG) one day before IUI and control group subjected to IUI alone.

Detailed description

A prospective randomized study included 210 patients with Unexplained infertility subjected to coupled ovarian stimulation and Intrauterine insemination (IUI). Two equal groups. Study group, subjected to uterine flushing with Human chorionic gonadotropin (HCG) one day before IUI and control group subjected to IUI alone.

Interventions

PROCEDUREHCG Uterine flushing

HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.

PROCEDUREIUI

Intrauterine insemination (IUI)

PROCEDUREVaginal flushing with 10 ml normal saline

Flushing of the vagina with 10 ml of saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

Vaginal flushing with 10 ml saline was performed in the control group

Intervention model description

intrauterine injection of human chorionic gonadotropin before intrauterine insemination (IUI) compared to IUI alone

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 37 Years

Healthy volunteers

Inclusion criteria

* Unexplained infertility (UI)

Exclusion criteria

* body mass index (BMI) ≥35 kg/m2, * Follicle Stimulating Hormone \>10 International Unit /Litter in early follicular phase, * diagnosed cause of infertility, menstrual cycle irregularity, * ovarian cysts, * sever cervical stenosis, * former IUI, * ongoing pregnancy and * renal or hepatic diseases were all the

Design outcomes

Primary

Measure	Time frame	Description
Live birth	10 months of randomization	Defined as pregnancies maintained beyond 20 weeks of gestation

Secondary

Measure	Time frame	Description
Clinical pregnancy	Two months after randomization	Defined by the presence of gestational sac with fetal heartbeats on ultrasound scan or histological identification of trophoblastic tissue.
Adverse effects	one hour of the procedure	Nausea, vomiting, and pain
Chemical pregnancy	One month after randomization	Defined as positive serum pregnancy test

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026